Australia Mammography Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Australia Mammography Market Trends and Insights

Rising Breast Cancer Incidence & Screening Targets

Australia logged 20,336 new breast-cancer diagnoses in 2025, sustaining policy pressure to lift BreastScreen participation toward the 70% goal that remains well out of reach at 49.6%. Indigenous participation sits even lower at 34.9%, prompting federal and state funding for mobile digital units that beam images to city radiologists. Five-year survival of 93% underlines the payoff from early detection, bolstering the case for additional mammography capacity. The forthcoming BreastScreen policy review is expected to link state funding to incremental participation gains, adding tailwinds for equipment orders. Closing the participation gap implies around 200,000 extra screens a year, which equates to 15-20 new systems if each unit handles 5,000 exams annually.

MBS Reimbursement for Digital & 3-D Upgrades

November 2025 reforms limit DBT claims to dense-breast or high-risk patients, yet the change drives hospitals to install density-assessment software that certifies eligibility and secures the AUD 150 (USD 100) higher reimbursement per study. Facilities mitigate the AUD 500,000-700,000 capital burden by pursuing volume deals with general-practice networks that fill schedules. Private radiology groups that once offered fee-for-service DBT now pivot to MBS-compliant pathways, which stabilize revenue but raise competition for the smaller qualifying cohort. The result is cautious hardware demand paired with robust software uptake.

Technology Shift to DBT & AI-Assisted Reading

Hologic introduced Genius AI Detection in March 2024, enabling one radiologist to supervise multiple AI-flagged worklists and trimming median diagnosis time by as much as 30%. DBT boosts detection by up to 2 cancers per 1,000 screens but multiplies image volume tenfold, creating a reading bottleneck that AI now relieves. Volpara Health Technologies supplies density and risk algorithms deployed across public and private networks, feeding risk-stratified pilots under the ROSA Breast program. Vendors increasingly package AI modules on a subscription basis, lowering upfront costs and extending the revenue tail beyond the equipment sale.

Risk-Based Screening & Density Notification Pilots

The ROSA Breast project modeled 160 scenarios and endorsed annual screening for high-risk women and triennial intervals for low-risk cohorts, a shift projected to cut over-diagnosis by 30% without sacrificing detection rates.^{[3]ROYAL AUSTRALIAN COLLEGE OF GENERAL PRACTITIONERS, “Risk-Based Breast Screening: Insights from the ROSA Breast Project,” RACGP, racgp.org.au} NSW and Victoria now mail density-notification letters that steer dense-breast women toward supplemental ultrasound or MRI, driving uptake of automated density-scoring platforms. While extended intervals dampen equipment utilization in low-risk groups, high-risk cohorts demand more advanced modalities, partially offsetting the volume loss. Draft federal imaging standards published in December 2025 point to mandatory density disclosure by 2028.

High Capital & Lifecycle Cost of DBT Systems

DBT units cost AUD 500,000-700,000 and require annual service contracts near AUD 50,000, double the outlay for 2D systems. With fewer than 3,000 screens per year, many regional hospitals face payback periods beyond the typical 7-year cycle, deterring upgrades. Larger data sets inflate storage and network expenses, and private centers without bulk-buy leverage defer investments in favor of software retrofits.

Radiologist & Technologist Workforce Shortages

Vacancy rates top 20% in Tasmania, the Northern Territory, and rural Queensland, where facilities depend on high-priced locums and cannot extend screening hours. Technician shortages add to the squeeze, as 30% of radiographers are over 55 and approaching retirement. AI can triage images but still requires final reads by AHPRA-licensed radiologists, preserving the bottleneck. Offshore reporting remains rare due to liability concerns.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product and Services: Software Subscriptions Outpace Hardware Sales

Mammography Systems still captured 73.64% of 2025 revenue, yet the category’s share is slipping as providers lengthen replacement intervals and retrofit existing units with AI modules. Software, Platforms & Services is advancing at a 13.64% CAGR, reflecting demand for cloud archiving, density analytics, and computer-aided detection that address workforce shortages. Hologic licenses Genius AI Detection at about AUD 30,000 per year, letting hospitals delay full upgrades while boosting sensitivity. Volpara’s per-study fees turn screening volume directly into SaaS revenue, offering resilience against hardware-cycle swings. The mammography market size attributed to Accessories & Consumables remains a stable mid-single-digit slice, tied closely to screen volume rather than technology mix.

Second-order effects reinforce the pivot. Draft national imaging standards specify automated dose logging and phantom tracking, functions delivered through software rather than hardware. Public hospitals in NSW and Victoria negotiate enterprise licenses that cap per-study costs, while smaller private clinics accept per-click billing to avoid upfront fees. This migration to recurring models improves cash flow for vendors and aligns expenses with utilization for providers, advancing a service-led trajectory in the mammography market.

By Technology: AI-Enabled CAD Disrupts Traditional Workflows

Full-Field Digital Mammography maintained a 46.83% share of 2025 revenue, yet AI-enabled CAD & Image-Triage is forecast to grow 14.53% annually through 2031 as radiology departments seek efficiency gains. DBT adoption tempers because the November 2025 MBS change restricts claims, but hospitals that already own DBT consoles hedge risk by adding triage software that accelerates reads. Photon-counting mammography remains pre-approval, though early studies highlight dose reductions that could tilt future procurement. The mammography market share led by AI technology will expand as regulatory clarity emerges on autonomous diagnosis, potentially doubling radiologist throughput and cementing AI as a core purchase criterion.

Regulatory pressure also supports tech turnover. NAS-2022 lowers allowable mean-glandular dose, a metric legacy 2D units struggle to meet without costly retrofits. Vendors offer firmware upgrades that cut exposure and add AI quality-control modules, extending life span but nudging providers toward newer platforms that bundle everything in one purchase. The mammography market size derived from DBT may plateau, yet total software spend keeps growing, offsetting slower hardware rollouts.

By End User: Diagnostic Centres Capture Share from Public Clinics

Hospitals retained 56.14% revenue share in 2025, but Diagnostic Centres are projected to expand 12.33% yearly, narrowing the gap as women favor shorter waits, after-hours slots, and bundled imaging. Private chains leverage agile capital budgets to acquire DBT units and AI suites ahead of public peers, monetizing premium services even after tighter MBS rules. Specialty Clinics that focus solely on breast imaging appeal to high-risk patients needing coordinated care, raising average revenue per screen. The mammography market size flowing through mobile vans and occupational programs remains small yet strategic, as it taps populations unreachable by fixed sites.

Public hospitals respond by outsourcing after-hours reading to private tele-radiology providers, sliding revenue toward the diagnostic-center segment. Leasing models help public sites acquire upgrades without large capital outlays, yet volume-linked payments expose them to participation fluctuations. As risk-based pilots lengthen intervals for low-risk groups, throughput in public clinics could dip, accelerating the shift of routine work to private centers that cross-sell adjunct services.

Geography Analysis

New South Wales, Victoria, and Queensland account for roughly 75% of national screening volume, anchoring vendor focus and early adoption campaigns. Density-notification pilots in NSW and Victoria drive automated-scoring software demand, whereas Queensland’s 12-unit mobile fleet broadens rural reach and is slated to add three more vans with satellite-ready DR in 2026. Western Australia and South Australia lean on tele-radiology networks that route images from sparsely populated areas to city radiologists, a model that may lift software revenue faster than hardware because it multiplies sites without multiplying specialists.

Tasmania and the Northern Territory struggle with sub-40% participation, hampered by long travel distances and intermittent radiologist availability. Recent van purchases aim to fill gaps, but maintenance and bandwidth remain hurdles. The Australian Capital Territory punches above its weight, showcasing the country’s highest DBT penetration as affluent demographics chase tech-first offerings. Geographic disparities might ease once a proposed federal imaging standard harmonizes QA and dose audit rules in 2028, yet until then, staggered state deadlines create a patchwork that vendors exploit through modular product lines.

Inter-state fleet ages vary, positioning NSW and Victoria for earlier replacement by 2027, while Queensland and Western Australia defer to 2028. Vendors sequence sales campaigns around these windows, bundling software that meets the strictest state standard to future-proof installations elsewhere. Such timing intricacies underscore why service contracts and upgrade paths now carry equal weight to headline hardware specs in purchase decisions across the mammography market.

Regulatory Landscape

Mammography systems and related software deployed in Australia are regulated as medical devices under the Therapeutic Goods Act 1989 and the Therapeutic Goods (Medical Devices) Regulations 2002, with suppliers typically requiring inclusion in the Australian Register of Therapeutic Goods (ARTG) before supply. In parallel, BreastScreen Australia services operate under the National Accreditation Standards (NAS), with accreditation decisions overseen through the program governance structure (including the National Quality Management Committee), which makes quality management and documented performance a procurement prerequisite for public screening providers.

Radiation safety and compliance obligations also sit at state and territory levels, for example through mammography-focused radiation standards issued by bodies such as the NSW Environment Protection Authority (EPA). The Therapeutic Goods Administration (TGA) continues post-market oversight via safety monitoring and public safety communications for breast screening devices, including cautionary guidance against non-evidence-based alternatives such as thermography, reinforcing mammography as the standard imaging modality in formal screening pathways.

Value Chain Analysis

The Australia mammography value chain is anchored by global OEMs (and their Australian subsidiaries) supplying full-field digital mammography and DBT systems, complemented by specialized software providers delivering AI-enabled CAD/image-triage, density assessment, archiving, and dose/QA workflow tools. Equipment and software typically move through importer-distributor networks and direct enterprise sales into hospitals, private diagnostic center chains, and BreastScreen services, with downstream value captured in installation, applications training, integration with PACS/RIS, and multi-year service agreements.

Compliance and operating requirements shape the post-sale portion of the chain. BreastScreen Australia accreditation under the NAS and state-based radiation standards drive ongoing QA, performance testing, and audit readiness, which increases demand for service engineers and software-enabled quality management. Workforce constraints highlighted in the market context further elevate the role of tele-radiology connectivity and AI workflow subscriptions as recurring components, expanding vendor involvement beyond the initial capital purchase into continuous optimization and compliance support.

Market Opportunities and Future Outlook

Software-led upgrades remain a practical entry point for vendors and providers, particularly where reimbursement and workforce constraints limit how quickly facilities can refresh hardware. The November 2025 Medicare Benefits Schedule (MBS) changes that narrowed DBT eligibility increase the need for automated breast-density assessment tools that document eligibility and standardize reporting. This dynamic supports opportunities in density analytics, audit-ready documentation, and workflow products that reduce reading burden, including AI-enabled image-triage modules, especially where sites keep legacy 2D/DBT systems in service but need performance and compliance uplift.

Public screening participation gaps and program modernization also support solutions that scale access without scaling on-site specialists. BreastScreen Australia continues to provide free mammograms for women over 40 on a two-year cycle, and the market context highlights ongoing mobile-van procurement and tele-radiology models to extend reach into regional and remote areas. Recent 2026 activity also reinforces the pathway toward AI-integrated screening operations, with BreastScreen South Australia commencing the BRAIx clinical trial comparing current double-reading approaches with an AI-supported model, and with large network-level software deployments such as Enlitic securing a multi-year Ensight subscription with Lumus Imaging for rollout across a national footprint.